NCT02316912View on ClinicalTrials.gov

First in Man Evaluation of Single and Multiple Doses of Oral ATX2417

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Allergy
Interventions
DRUG

ATX2417

Randomised double blind parallel group ascending dose assessment

DRUG

Placebo

Randomised double blind parallel group ascending dose assessment

Trial Locations (1)

CF48 4DR

Simbec Research, Merthyr Tydfil

Sponsors
All Listed Sponsors
collaborator

Simbec Research

INDUSTRY

lead

Atopix Therapeutics, Ltd.

INDUSTRY

NCT02316912 - First in Man Evaluation of Single and Multiple Doses of Oral ATX2417 | Biotech Hunter | Biotech Hunter